AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 6-KAUG 132 min read$AFYA

Afya Ltd (AFYA): Financial results for Q2 2026

Afya Ltd (AFYA) furnished an SEC Form 6-K — earnings release. Afya Limited Announces Second-Quarter and First-Half 2026 Financial Results R$448 Million Returned to Shareholders 106% of 1H26 FCFE Distributed Through Dividends and Share Repurchases Belo Horizonte, Brazil, August 13, 2026 – Afya Limited (Nasdaq: AFYA; B3: A2FY34) (“Afya” or th

Original reporting
SEC EDGAR 6-K
Published Aug 13, 2026, 8:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 28, 2026, 6:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$AFYA
Neutral
medium confidence
Mentioned
$AFYA
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 6-K
Decision brief

The 30-second read

$AFYANeutralMed
01

Why it matters

The earnings release provides fresh financial metrics, confirming growth and strong cash generation, which may influence short‑term price action and sector sentiment.

02

Market read

First‑time earnings disclosure for Afya offers new data that could move the stock and influence Brazil healthcare equities.

03

What to watch

Potential headwinds from regulatory changes in Brazil's healthcare financing and competition from new entrants.

Relevance 7/10Novelty 8/10Timing: Q2 2026 earnings release on Aug 13

Background

Afya Ltd, a Nasdaq-listed Brazilian medical education and practice solutions provider, filed a Form 6‑K earnings release for Q2 2026.

Company-level read

Ticker impact

$AFYANeutralMedium confidence
Context

Afya Ltd reported Q2 2026 revenue of R$972.1 million and net income of R$201.3 million, with adjusted EBITDA of R$406.5 million.

Expected impact

Potential modest upside of 3-5% if market digests the cash return and earnings beat.

Evidence & confidence

Revenue and earnings grew YoY, free cash flow returned to shareholders exceeds FCFE, but margins slightly compressed; no major guidance shift.

Market effects

Sector

Positive signal for Brazilian medical education and health services sector due to revenue growth and cash returns.

Regional

May boost investor sentiment toward Brazil-listed healthcare stocks.

Global

Limited; primarily affects regional and sector-specific investors.

Counterpoint

What could challenge this read

If margin compression continues, the stock could face pressure despite cash returns.

Key entities

  • Company
    Afya Ltd

    Nasdaq-listed Brazilian medical education and practice solutions provider.

  • Rating Agency
    Moody's

    Reaffirmed Afya’s AAA.br credit rating with stable outlook on May 5, 2026.

  • Executive
    Marcelo Ken Suhara

    Appointed Chair of Afya’s Audit, Risks and Ethics Committee on July 27, 2026.

Read at source← All news

Related articles

OCT 7
$AFYAHigh

JPMorgan upgrades Afya stock rating on merger synergies

JPMorgan upgraded Afya Ltd. (AFYA) to Overweight, citing merger synergies of R$1.8 billion and a premium higher education company. The price target was lowered to $19.00 from $21.00. Afya reported Q2 2026 revenue growth of 6% and H1 growth of 7%, with net income rising 14% in Q2 and 7% in H1. The company trades at a P/E ratio of 8 and a 23% free cash flow yield.

investing.com1 min
AUG 24
$AFYAMed

Afya and Yduqs Confirm Merger Talks of Brazil’s Education Giants

Afya and Yduqs, Brazil's largest medical-education network and education group, confirmed early-stage merger talks on 24 August 2026. Yduqs shares rose 12.1% in São Paulo, while Afya's shares in New York increased 0.77%. The companies' second-quarter financials showed contrasting performances, with Afya in a stronger position. No binding agreements or details have been finalized, and both companies emphasized the preliminary nature of the discussions.

riotimesonline.com2 min
AUG 21
$AFYAMedAI 8/10

Afya (AFYA) Q2 2026 Earnings Call Transcript

Afya (AFYA) reported Q2 2026 revenue of BRL 1.985 billion, up 7% YoY. Adjusted EBITDA rose 3% to BRL 918 million, while net income increased 7% to BRL 463 million. The company faces AI competition in clinical decision tools but is integrating AI into its iClinic platform. Management reaffirmed its full-year EBITDA guidance of BRL 1.7-1.8 billion.

fool.com3 min